Loading
ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.
Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.
ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.
Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity.
No product in this corpus aims at ID3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ID3: RNA tissue enhanced (blood vessel 461 nTPM); blood lineage group enriched (B-cells 320 nTPM, T-cells 178 nTPM); high antibody staining in 30 normal tissues; highest cancer staining skin cancer (7 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (Burkitt lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q02535; CIViC gene ID3; IntOGen ID3; Human Protein Atlas ID3 tissue; Open Targets ENSG00000117318 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Ellmeier et al, EMBO J, 1992, "Mutually exclusive expression of a helix-loop-helix gene and N-myc in human neuroblastomas and in normal development". Source.
Sources: HGNC HGNC:5362 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02535 (protein name, function text, keywords and locations (REST API)); CIViC gene ID3 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000117318 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.61, Burkitt lymphoma 0.51 (GraphQL API, CC0)); IntOGen ID3 (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation. Inhibits the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer. Location: Nucleus (UniProt). Locus 1p36.12 (HGNC).
RNA: tissue enhanced (blood vessel 461 nTPM), detected in all normal tissues. Blood: group enriched (B-cells 320 nTPM, T-cells 178 nTPM).
Medium: Adipose tissue, Caudate, Cerebellum, Cerebral cortex, Duodenum, Hippocampus, Kidney, Lung.
RNA cancer enhanced: Glioblastoma Multiforme 285 pTPM.
Medium only: liver cancer, prostate cancer, stomach cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ID3" OR ABSTRACT:"ID3" OR TITLE:"inhibitor of DNA binding 3" OR ABSTRACT:"inhibitor of DNA binding 3" OR TITLE:"DNA-binding protein inhibitor ID-3" OR ABSTRACT:"DNA-binding protein inhibitor ID-3" OR TITLE:"HEIR-1" OR ABSTRACT:"HEIR-1" OR TITLE:"bHLHb25" OR ABSTRACT:"bHLHb25") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ID3, not a curated reading list.
Shares The cell-cycle engine (cyclins & CDKs), B-cell receptor / BTK signalling (to NF-κB), Burkitt lymphoma, PI3K / AKT / mTOR.
Shares The cell-cycle engine (cyclins & CDKs), B-cell receptor / BTK signalling (to NF-κB), Burkitt lymphoma, PI3K / AKT / mTOR.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).